Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €39.01 EUR
Change Today -0.44 / -1.12%
Volume 0.0
SGT On Other Exchanges
Symbol
Exchange
Berlin
As of 2:08 AM 06/2/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

21823 30th Drive SE

Bothell, WA 98021

United States

Phone: 425-527-4000

Fax: 425-527-4001

Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of targeted therapies for the treatment of cancer. ADCETRIS The company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing its proprietary technology. ADCETRIS received accelerated approval in the United States in 2011, conditional marketing authorization in the European Union in 2012 and approval with conditions in Canada in 2013 for patients with relapsed Hodgkin lymphoma or relapsed systemic anaplastic large cell lymphoma (sALCL). The company is in the process of collaborating with Takeda Pharmaceutical Company Limited (Takeda) to develop and commercialize ADCETRIS on a global basis. Under this collaboration, the company retains commercial rights for ADCETRIS in the United States and Canada, and Takeda has commercial rights in the rest of the world. ADCETRIS is approved in 50 countries, including Japan, Australia, Switzerland, South Korea, Singapore and Mexico, and Takeda continues to pursue marketing authorizations in multiple other countries. The company and Takeda have a development strategy for ADCETRIS evaluating its potential application in earlier lines of therapy for patients with Hodgkin lymphoma or mature T-cell lymphoma (MTCL), including sALCL and in other CD30-positive malignancies. In addition to ADCETRIS, the company’s pipeline includes six clinical-stage ADC programs consisting of SGN-CD33A, SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and SEA-CD40, which is based on sugar-engineered antibody, or SEA, technology. The company also has collaborations for ADC technology with biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd., or AbbVie; Bayer Pharma AG, or Bayer; Celldex Therapeutics, Inc., or Celldex; Genentech, Inc., a member of the Roche Group, or Genentech; GlaxoSmithKline LLC, or GSK; Pfizer, Inc., or Pfizer; PSMA Development Company LLC, a subsidiary of Progenics Pharmaceuticals Inc., or Progenics; and Takeda; as well as ADC co-development agreements with Agensys, Inc., an affiliate of Astellas Pharma, Inc., or Agensys; Genmab A/S, or Genmab; and Oxford BioTherapeutics Ltd., or OBT. For ADCETRIS and its related ADC technology, including certain methods of treatment using ADCETRIS, the company’s 19 issued patents would expire between 2015 and 2031 in the United States and Europe SGN-CD33A SGN-CD33A is an ADC composed of an anti-CD33 monoclonal antibody linked to a potent PBD dimer using proprietary ADC technology, and is a product candidate for the treatment of AML. SGN-CD33A targets CD33, a protein that is expressed on most AML cells. SGN-CD33A employs the company’s newest proprietary ADC technology. This technology is comprised of a PBD dimer, which is a potent cell-killing agent that works by a different mechanism than auristatins, linked to an engineered antibody called EC-mAb, resulting in uniform drug-loading of two PBD dimers per antibody. For SGN-CD33A and the company’s related ADC technology, its five issued patents would expire between 2027 and 2030 in the United States and Europe. SGN-CD19A SGN-CD19A is an ADC composed of an anti-CD19 monoclonal antibody linked to a potent auristatin compound using proprietary ADC technology, and is a product candidate for the treatment of hematologic malignancies. CD19 is a B-cell antigen that is expressed in non-Hodgkin lymphoma, chronic lymphocytic leukemia and acute lymphoblastic leukemia (ALL). SGN-LIV1A SGN-LIV1A is an ADC composed of an anti-LIV-1 monoclonal antibody linked to a potent auristatin compound using proprietary ADC technology, and is a product candidate for the treatment of LIV-1-positive metastatic breast cancer. In 2013, the company initiated a phase 1, open-label, dose-escalation clinical trial to evaluate the safety and antitumor activity of SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer. SGN-70A SGN-CD70A is an ADC composed of an anti-CD70 EC-mAb linked to a potent PBD dimer using proprietary ADC technology, and is a product candidate for the treatment of CD70-positive renal cell carcinoma and non-Hodgkin lymphoma. SEA-CD40 SEA-CD40 utilizes the company’s SEA technology to produce a non-fucosylated antibody targeting CD40. The company initiated a phase 1, open label, multi center, dose escalation trial of SEA-CD40 in multiple solid tumors. ASG-22ME ASG-22ME is an ADC composed of an anti-Nectin-4 monoclonal antibody linked to a potent auristatin compound using proprietary ADC technology. Nectin-4 is a novel target expressed in multiple cancers including bladder, breast, lung and pancreatic cancers. The company is in the process of developing ASG-22ME as a product candidate for the treatment of solid tumors under co-development collaboration with Agensys, Inc. ASG-15ME ASG-15ME is an ADC composed of an anti- SLITRK6 monoclonal antibody linked to a potent auristatin compound using proprietary ADC technology. SLITRK6 is a novel target expressed in bladder and lung cancer. The company is in the process of developing ASG-15ME as a product candidate for the treatment of bladder cancer under co-development collaboration with Agensys, Inc. Strategy The company’s strategy is to become a leading developer and marketer of targeted therapies for cancer. Main elements of its strategy are as follows: successfully execute ADCETRIS commercial plan; expand the therapeutic potential of ADCETRIS; continue to develop other pipeline programs; continue to leverage industry-leading ADC Technology; support future growth of pipeline through internal research efforts and strategic in-licensing; and enter into strategic product collaborations to generate capital and supplement internal resources. Research and Development As of December 31, 2014, the company recorded $230.7 million in research and development expenses. History Seattle Genetics, Inc. was founded in 1997. The company was incorporated in Delaware in 1997.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SGT:GR €39.01 EUR -0.44

SGT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ARIAD Pharmaceuticals Inc $8.92 USD -0.26
Genmab A/S kr606.50 DKK +9.00
Insys Therapeutics Inc $59.00 USD -0.60
MorphoSys AG €66.01 EUR -0.128
Pfizer Ltd/India 2,171 INR -21.95
View Industry Companies
 

Industry Analysis

SGT

Industry Average

Valuation SGT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 17.8x
Price/Book 25.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 16.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SEATTLE GENETICS INC, please visit www.seattlegenetics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.